US stock indexes rebounded on Wednesday, August 19, recovering from the previous session's steep technology selloff as easing government bond yields boosted investor risk appetite, while a dramatic rally in shares of vaccine maker Moderna drove healthcare stocks to a record high.

Moderna's Cancer Trial Breakthrough

Moderna shares more than doubled after the company announced that its personalized mRNA cancer therapy, developed jointly with Merck, cut the risk of melanoma recurrence and spread in a late-stage clinical trial. Merck shares jumped 11.2%, making it the biggest gainer on the blue-chip Dow. The rally spilled over into the broader biotech sector: Novavax rose 6%, while US-listed shares of BioNTech surged 21%. The S&P 500 healthcare sector climbed 2.9% to a record high, providing the single biggest boost to the benchmark index of any of its 11 major industry groups.

Treasury Yields Retreat After Historic Highs

The rally in risk assets was underpinned by a pullback in bond yields, a day after the 30-year Treasury yield hit its highest level since 2007. Both the 30-year and 10-year Treasury yields eased on Wednesday after the US Treasury announced it would double the size of its liquidity support buyback operations for longer-dated bonds. "The risk-on trade is trying to hang on to the lifeline that Treasury Secretary Bessent sent," said Carol Schleif, chief market strategist at BMO Private Wealth, noting that higher rates "could potentially impact the AI trade," since technology companies have been issuing significant debt and equity, alongside deploying their own cash, to fund AI data center construction.

A Muted Reaction to Fed Minutes

Investors largely shrugged off the release of minutes from the Federal Reserve's July policy meeting, which revealed deepening concern among officials about inflation, with "several" policymakers reportedly ready to support a rate hike and "many" indicating a hike would be necessary if inflation fails to decline toward the Fed's 2% target. Sam Stovall, chief investment strategist at CFRA Research, framed the underlying tension bluntly: "Inflation does remain a concern and elevated oil prices are contributing to that. If the Federal Reserve is not going to do anything about it, the bond market will."

Tech Stocks Stayed Flat

Unlike the broad-based healthcare rally, information technology stocks on the S&P 500 were roughly flat Wednesday, still digesting the prior session's sharp selloff. Chipmaker Broadcom fell 4% after Marvell Technologies issued Google parent Alphabet a warrant to buy a stake worth approximately $12.18 billion — a move that appeared to weigh on sentiment toward Broadcom specifically amid the broader semiconductor sector's ongoing volatility.

Strong Retail Earnings Add to the Upbeat Tone

Corporate earnings provided additional support. Target rose 5% after raising its annual sales forecast, while Lowe's gained 2.4% despite trimming its own annual sales growth outlook. Estée Lauder jumped more than 16.7% after the cosmetics maker forecast annual profit above Wall Street estimates — together painting a picture of resilient consumer-facing earnings even amid broader macro uncertainty.

Oil and the Strait of Hormuz Standoff Continue

Brent crude futures settled higher, with progress on Middle East diplomacy remaining unclear. President Trump said no talks were currently taking place with Iran and insisted the Strait of Hormuz was open, directly contradicting Iran's own assertion that the strait remained shut to shipping — the latest example of conflicting signals continuing to inject uncertainty into oil markets.

Market Breadth

Advancing issues outnumbered decliners by a 1.9-to-1 ratio on the NYSE, where there were 263 new highs against just 93 new lows. On the Nasdaq, 2,855 stocks rose while 1,967 fell, a roughly 1.45-to-1 advancing ratio. The S&P 500 posted 18 new 52-week highs and no new lows, while the Nasdaq Composite recorded 106 new highs against 89 new lows — broadly healthy breadth figures suggesting the rebound extended well beyond just the day's headline healthcare and retail winners.

The Bigger Picture

Wednesday's rebound illustrates how tightly Wall Street's daily moves remain tied to the interplay between bond yields, Fed policy expectations, and individual corporate catalysts — with a single breakthrough drug trial result proving powerful enough to offset broader macro uncertainty and lift the entire market for a session. For live market data, see CNBC Markets.

With inflation concerns, elevated oil prices, and Fed rate uncertainty all still simmering in the background, Wednesday's rally offered a welcome reprieve — but one analysts caution may prove more about Treasury's bond-support intervention and a single blockbuster drug trial than a durable shift in the market's underlying risk calculus.